Logo image of SGEN

SEAGEN INC (SGEN) Stock Fundamental Analysis

NASDAQ:SGEN - Nasdaq - US81181C1045 - Common Stock - Currency: USD

228.74  -0.16 (-0.07%)

After market: 228.95 +0.21 (+0.09%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SGEN. SGEN was compared to 572 industry peers in the Biotechnology industry. SGEN has a great financial health rating, but its profitability evaluates not so good. SGEN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SGEN has reported negative net income.
SGEN had a negative operating cash flow in the past year.
In the past 5 years SGEN reported 4 times negative net income.
SGEN had negative operating cash flow in 4 of the past 5 years.
SGEN Yearly Net Income VS EBIT VS OCF VS FCFSGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 500M -500M

1.2 Ratios

With an excellent Return On Assets value of -20.64%, SGEN belongs to the best of the industry, outperforming 82.06% of the companies in the same industry.
The Return On Equity of SGEN (-29.41%) is better than 81.40% of its industry peers.
Industry RankSector Rank
ROA -20.64%
ROE -29.41%
ROIC N/A
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A
SGEN Yearly ROA, ROE, ROICSGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 10 -10 -20

1.3 Margins

The Gross Margin of SGEN (75.39%) is better than 84.88% of its industry peers.
In the last couple of years the Gross Margin of SGEN has declined.
The Profit Margin and Operating Margin are not available for SGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%
SGEN Yearly Profit, Operating, Gross MarginsSGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 -40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

SGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SGEN has more shares outstanding
SGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGEN Yearly Shares OutstandingSGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
SGEN Yearly Total Debt VS Total AssetsSGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B 4B

2.2 Solvency

SGEN has an Altman-Z score of 23.31. This indicates that SGEN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of SGEN (23.31) is better than 94.68% of its industry peers.
There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.31
ROIC/WACCN/A
WACC10.94%
SGEN Yearly LT Debt VS Equity VS FCFSGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 1B 2B 3B

2.3 Liquidity

A Current Ratio of 2.67 indicates that SGEN has no problem at all paying its short term obligations.
SGEN's Current ratio of 2.67 is on the low side compared to the rest of the industry. SGEN is outperformed by 73.26% of its industry peers.
SGEN has a Quick Ratio of 2.12. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.12, SGEN is doing worse than 76.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2.12
SGEN Yearly Current Assets VS Current LiabilitesSGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B

More info and screens

7

3. Growth

3.1 Past

The earnings per share for SGEN have decreased strongly by -16.23% in the last year.
The Revenue has grown by 23.40% in the past year. This is a very strong growth!
Measured over the past years, SGEN shows a very strong growth in Revenue. The Revenue has been growing by 32.40% on average per year.
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%

3.2 Future

The Earnings Per Share is expected to grow by 32.31% on average over the next years. This is a very strong growth
SGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.49% yearly.
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SGEN Yearly Revenue VS EstimatesSGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
SGEN Yearly EPS VS EstimatesSGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGEN. In the last year negative earnings were reported.
Also next year SGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGEN Price Earnings VS Forward Price EarningsSGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGEN Per share dataSGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

SGEN's earnings are expected to grow with 29.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.92%
EPS Next 3Y29.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEAGEN INC

NASDAQ:SGEN (12/13/2023, 8:12:24 PM)

After market: 228.95 +0.21 (+0.09%)

228.74

-0.16 (-0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-01 2023-11-01/bmo
Earnings (Next)02-13 2024-02-13/amc
Inst Owners0.21%
Inst Owner Change0%
Ins Owners0.86%
Ins Owner Change0%
Market Cap43.15B
Analysts72.17
Price Target233.48 (2.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.9%
Min EPS beat(2)-42.41%
Max EPS beat(2)-37.4%
EPS beat(4)1
Avg EPS beat(4)-16.67%
Min EPS beat(4)-42.41%
Max EPS beat(4)24.39%
EPS beat(8)3
Avg EPS beat(8)-5.14%
EPS beat(12)5
Avg EPS beat(12)-16.24%
EPS beat(16)8
Avg EPS beat(16)36.61%
Revenue beat(2)2
Avg Revenue beat(2)2.94%
Min Revenue beat(2)0.14%
Max Revenue beat(2)5.73%
Revenue beat(4)3
Avg Revenue beat(4)3.09%
Min Revenue beat(4)-1.45%
Max Revenue beat(4)7.95%
Revenue beat(8)7
Avg Revenue beat(8)5.12%
Revenue beat(12)10
Avg Revenue beat(12)4.52%
Revenue beat(16)14
Avg Revenue beat(16)12.68%
PT rev (1m)0%
PT rev (3m)1.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-47.4%
EPS NY rev (1m)-17.92%
EPS NY rev (3m)-19.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)101391%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)0.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.76
P/FCF N/A
P/OCF N/A
P/B 16.92
P/tB 20.99
EV/EBITDA N/A
EPS(TTM)-4.01
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-3.72
FCFYN/A
OCF(TTM)-2.86
OCFYN/A
SpS12.19
BVpS13.52
TBVpS10.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.64%
ROE -29.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.39%
FCFM N/A
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%
F-Score3
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 219.65%
Cap/Sales 7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2.12
Altman-Z 23.31
F-Score3
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)115.85%
Cap/Depr(5y)145.31%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%
EBIT growth 1Y-18.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.02%
EBIT Next 3Y33.65%
EBIT Next 5Y31.94%
FCF growth 1Y-758.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1946.21%
OCF growth 3YN/A
OCF growth 5YN/A